See more : Holley Inc. (HLLY) Income Statement Analysis – Financial Results
Complete financial analysis of Sigilon Therapeutics, Inc. (SGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigilon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Autoneum Holding AG (AUTN.SW) Income Statement Analysis – Financial Results
- Compagnie Financière Tradition SA (CFNCF) Income Statement Analysis – Financial Results
- Koç Holding A.S. (KCHOL.IS) Income Statement Analysis – Financial Results
- Zero One Technology Co., Ltd. (3029.TW) Income Statement Analysis – Financial Results
- Vale S.A. (VALE3.SA) Income Statement Analysis – Financial Results
Sigilon Therapeutics, Inc. (SGTX)
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 37.63M | 65.07M | 53.49M | 48.11M | 21.04M |
| General & Administrative | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Other Expenses | 1.45M | 55.00K | -89.00K | -6.00K | -81.00K |
| Operating Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Cost & Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Interest Income | 946.00K | 258.00K | 312.00K | 1.06M | 698.00K |
| Interest Expense | 2.29M | 1.99M | 1.20M | 650.00K | 289.00K |
| Depreciation & Amortization | 2.40M | 313.00K | 223.00K | 1.73M | 374.00K |
| EBITDA | -41.27M | -75.32M | -52.42M | -42.40M | -22.08M |
| EBITDA Ratio | -318.84% | -784.70% | -391.95% | -299.51% | -476.26% |
| Operating Income | -43.67M | -75.64M | -52.64M | -44.12M | -23.08M |
| Operating Income Ratio | -337.35% | -787.96% | -393.61% | -311.71% | -497.63% |
| Total Other Income/Expenses | 105.00K | -1.68M | -1.97M | 198.00K | 310.00K |
| Income Before Tax | -43.56M | -77.31M | -54.61M | -43.93M | -22.77M |
| Income Before Tax Ratio | -336.53% | -805.41% | -408.31% | -310.31% | -490.94% |
| Income Tax Expense | -105.00K | 925.00K | 259.00K | 644.00K | 599.00K |
| Net Income | -43.46M | -78.24M | -54.87M | -44.57M | -22.77M |
| Net Income Ratio | -335.72% | -815.04% | -410.25% | -314.86% | -490.94% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| Weighted Avg Shares Out | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
| Weighted Avg Shares Out (Dil) | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer
Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
Sigilon Therapeutics to Present at Barclays Global Healthcare Conference
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
Source: https://incomestatements.info
Category: Stock Reports